Metallic colloid nanotechnology, applications in diagnosis and therapeutics

Current Pharmaceutical Design

Volumn 11, Issue 16, 2005, Pages 2091-2105

  Sonvico, Fabio ^a,b   Dubernet, Catherine ^a   Colombo, Paolo ^b   Couvreur, Patrick ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Biomedical applications; Biosensors; Drug delivery; Hyperthermia; Magnetic resonance imaging; Metal particles; Nanoparticles; Quantum dots

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CATION; COMPLEMENTARY DNA; CYTOTOXIC AGENT; DNA VACCINE; DOXORUBICIN; FERRIC HYDROXIDE; GOLD 198; INSULIN; LIPOSOME; MAGNETITE; QUANTUM DOT; SUPERPARAMAGNETIC IRON OXIDE; COLLOIDAL GOLD; DIAGNOSTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTIFICIAL EMBOLISM; CELL SELECTION; COLLOID; CONTRAST ENHANCEMENT; CONTRAST RADIOGRAPHY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG MONITORING; DRUG POTENTIATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GASTROINTESTINAL RADIOGRAPHY; GLIOMA; HUMAN; HYPERTHERMIA; HYPERTHERMIC THERAPY; LIVER CANCER; LIVER METASTASIS; MAGNETIC FIELD; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL BIOSENSOR; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SPLEEN CANCER; ANIMAL; METHODOLOGY;

ANIMALS; GOLD COLLOID; GOLD COLLOID, RADIOACTIVE; HUMANS; NANOTECHNOLOGY;

EID: 20044366398     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054065738     Document Type: Review

References (186)

1. Bogunia-Kubik K, Suguisaka M. From molecular biology to nanotechnology and nanomedicine. Biosystems 2002; 65: 123-138.
2. Ohgushi M, Nagayama K, Wada A. Dextran magnetite: a new relaxation agent and its application to T2 measurements in gel systems. J Magn Reson 1978; 29: 599-601.
3. Weissleder R, Papisov M. Pharmaceutical iron oxides for MR imaging. Rev Magn Reson Med 1992; 4: 1-20.
4. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. J Drug Target 1998; 6: 167-174.
5. Kim DK, Zhang Y, Voit W, Rao KV, Muhammed M. Synthesis and characterisation of surfactant-coated superparamagnetic monodispersed iron oxide nanoparticles. J Magn Magn Mater 2001; 225: 30-36.
6. Butterworth MD, Illum L, Davies SS. Preparation of ultrafine silica- and PEG-coated magnetite particles. Colloids Surf A 2001; 179: 93-102.
7. Kim DK, Mikhaylova M, Zhang Y, Muhammed M. Protective coating of superparamagnetic iron oxide nanoparticles. Chem Mater 2003; 15: 1617-1627.
8. Chouly C, Pouliquen D, Lucet I, Le Jeune JJ, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsulation 1996; 13: 245-255.
9. Pouliquen D, Le Jeune JJ, Perdrisot R, Ermias A, Jallet P. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn Reson Imaging 1991; 9: 275-283.
10. Okon E, Pouliquen D, Okon P, Kovaleva ZV, Stepanova TP, Lavit SG, et al. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study. Lab Invest 1994; 71: 895-903.
11. Hahn PF, Stark DD, Lewis JM, Saini S, Elizondo G, Weissleder R, et al. First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging. Radiology 1990; 175: 695-700.
12. Rubin DL, Muller HH, Young SW, Hunke WA, Gorman WG. Optimization of an oral magnetic particle formulation as a gastrointestinal contrast agent for magnetic resonance imaging. Invest Radiol 1994, 29: 81-86.
13. Chachuat A, Bonnemain B. European clinical experience with Endorem. A new contrast agent for liver MRI in 1000 Patients. Radiologe 1995, 35: S274-276.
14. Kubaska S, Sahani DV, Saini S, Hahn PF, Halpern E. Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterisation. Clin Radiol 2001; 56: 410-415.
15. Weissleder R, Elizondo G, Stark D, Hahn PF, Marfil J, Gonzales JF, et al. The diagnosis of splenic lymphoma by MR imaging: value of superparamagnetic iron oxide. AJR Am J Roentgen 1989; 152: 175-180.
16. Päuser S, Reszka R, Wagner S, Wolf KJ, Buhr HJ, Berger G. Liposome-encapsulated superparamagnetic iron oxide particles as markers in an MRI-guided search for tumor-specific drug carrier. Anticancer Drug Des 1997, 12: 125-135.
17. Elmi MM, Sarbolouki MN. A simple method for preparation of immuno-magnetic liposomes. Int J Pharm 2001; 215: 45-50.
18. 3H](6)-5-Fluorouracil-loaded PLGA microspheres. Eur J Pharm Biopharm 2002; 53: p. 293-299, (2002).
19. Irgartua M, Saulnier P, Heurtault B, Pech, Proust JE, Pedraz JL, et al. Development and characterisation of solid lipid nanoparticles loaded with magnetite. Int J Pharm 2002; 233: 149-157.
20. Iannone A, Magin RL, Walczak T, Federico M, Swartz HM, Tomasi A, et al. Blood clearance of dextran magnetite particles determined by a noninvasive in vivo ESR method. Magn Reson Med 1991; 22: 435-442.
21. Weissleder R, Bogdanov A, Neuwelt EA, Papisov M. Long-circulating iron oxides for MR imaging. Adv Drug Deliv Rev 1995, 16: 321-334.
22. Bogdanov AA, Lewin M, Weissleder R. Approaches and agents for imaging the vascular system. Adv Drug Deliv Rev 1999; 37: 279-293.
23. Turetschek K, Hubner S, Floyd E, Helbich T, Roberts TPL, Shames DM, et al. MR imaging characterisation of microvessels in experimental breast tumors by using a particulate contrast agent with histopatologic correlation. Radiology 2001; 218: 562-569.
24. Rozenman Y, Zou XM, Kantor HL. Cardiovascular MR imaging with iron oxide particles: utility of a superparamagnetic contrast agent and the role of diffusion signal loss. Radiology 1990; 175: 655-659.
25. Greiner N, Basseau F, Ries M, Tyndal B, Jones R Moonen C. Functional MRI of the kidney. Abdom Imaging 2003; 28: 164-175.
26. Anzai Y, McLachlan S, Morris M, Saxton R, Lufkin RB. Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck. AJNR Am J Neuroradiol 1994; 15: 87-94.
27. Lind K, Kresse M, Debus NP, Müller RH. A novel formulation for superpapamagnetic iron oxide (SPIO) particles enhancing MR lymphograpy: comparison of physicochemical properties and the in vivo behaviour. J Drug Target 2002; 10: 221-230.
28. Dousset V, Ballarino L, Delalande C, Coussemacq M, Canioni P, Petry KG, et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-Weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. AJNR Am J Neuroradiol 1999; 20: 223-227.
29. Moore A, Weissleder R, Bogdanov A. Uptake of dextran-coated monocrystalline iron oxide in tumor cells and macrophages. J Magn Reson Imaging 1997, 7: 1140-1145.
30. Moore A, Basilion JP, Chiocca EA Weissleder R. Measuring transferrin receptor gene expression by NMR imaging. Biochim Biophys Acta 1998; 1402: 239-242
31. Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, Cohen JI, et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am J Neuroradiol 2002; 23: 510-519.
32. Remsen LG, McCormick CI, Roman-Goldstein S, Nilaver G, Weissleder R, Bogdanov A, et al. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive niagnosis. AJNR Am J Neuroradiol 1996; 17: 411-418.
33. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003; 49: 403-408.
34. Bogdanov A, Weissleder R. The development of in vivo imaging systems to study gene expression. Trends Biotechnol 1998; 16: 5-10.
35. Bulte JW, Zhang SC, van Gelderen P, Herynek V, Jordan EK, Duncan ID, et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci USA 1999; 96: 15256-15261.
36. Dodd SJ, Williams M, Suhan JP, Williams DS, Koretsky AP, Ho C. Detection of single mammalian cells by high-resolution magnetic resonance imaging. Biophys J 1999; 76: 103-109.
37. Foster-Gareau P, Heyn C, Alejski A, Rutt BK. Imaging single mammalian cells with a 1.5 T clinical MRI scanner. Magn Reson Med 2003; 49: 968-971.
38. Hinds KA, Hill JM, Shapiro EM, Laukkanen MO, Silva AC, Combs CA, et al. Highly efficient endosomal labelling of progenitor and stem cells with Irge magnetic particles allows magnetic resonance imaging of single cells. Blood 2003; 102: 867-872.
39. Lewin M, Carlesso N, Tung CH, Tang XV, Cory D, Scadden DT, et al. Tat Peptide-derivatized magnetic particles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000; 18: 410-414.
40. Jendelova P, Herynek V, DeCroos J, Glogarova K, Andersson B, Hajek M, et al. Imaging of the fate of implanted bone marrow stromal cells labeled with superparamagnetic nanoparticles. Magn Reson Med 2003; 50: 767-776.
41. Chemla YR, Grossman HL, Poon Y, McDermott R, Stevens R, Alper MD, et al. Ultrasensitive magnetic biosensor for homogeneous immunoassay. Proc Natl Acad Sci USA 2000; 97: 14268-14272.
42. Taton TA. Nanostructures as tailored biological probes. Trends Biotechnol 2002; 20: 277-279.
43. Glesne DA, Bridging the electrochemical and biological worlds with hybrid nanocomposites. Trends Biotechnol 2003; 21: 379-380.
44. Schultz DA. Plasmon resonant particles for biological detection. Curr Opin Biotechnol 2003; 14: 13-22.
45. Enünstün BV, Turkevich J. Coagulation of colloidal gold. J Am Chem Soc 1963; 85: 3317-3328.
46. Horisberger M. Colloidal gold: a cytochemical marker for light and fluorescent microscopy and for transmission and scanning electron microscopy. Scanning Electron Microsc 1981; 11: 9-31.
47. Slot JV, Geuze HJ. A new method of preparing gold probes for multiple-labeling cytochemistry. Eur J Cell Biol 1985; 38: 87-93.
48. Liu T, Tang J, Zhao H, Dieng Y, Jiang L. Particle size effect of the DNA sensor amplified with gold nanoparticles. Langmuir 2002; 18: 5624-5626.
49. Yin Y, Li ZY, Zhong Z, Gates B, Xia Y, Venkateswaran S. Synthesis and characterisation of stable aqueous dispersion of silver nanoparticles through the Tollens process. J Mater Chem 2002; 12: 522-527.
50. Link S, El-Sayed MA. Shape and size dependence of radaitive, non-raditive, and photothermal properties of gold nanocrystals. Int Rev Phys Chem 2000; 19: 409-453.
51. Duval-Malinsky M, Kelly KL, Schatz GC, Van Duyne RP. Chain length dependence and sensing capabilities of the localized surface plasmon resonance of silver nanoparticles chemically modified with alkanethiol self-assembled monolayers. J Am Chem Soc 2001; 123: 1471-1482.
52. Lowe AB, Sumerlin BS, Donovan MS, McCormick CL. Facile preparation of transition metal nanoparticles stabilized by well defined (co)polymers synthetized via aqueous reversible addition-fragmentation chain transfer polymerisation. J Am Chem Soc 2002; 124: 11562-11563.
53. Mangeney C, Ferrage F, Aujard I, Marchi-Artzner V, Jullien L, Ouari O, et al. Synthesis and properties of water-Soluble gold colloids covalently derivatized with neutral polymer monolayers. J Am Chem Soc 2002; 124: 5811-5821.
54. Storhoff JJ, Elghanian R, Mirkin CA, Letsinger RL. Sequence-dependent stability of DNA-modified gold nanoparticles. Langmuir 2002; 18: 6666-6670.
55. Musson U, Fägerstam LG, Iversson B, Johnsson B, Karlsson R, Lundh K, et al. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 1991; 11: 620-627.
56. Myszka DG, Rich RL. Implementing surface plasmon resonance biosensor in drug discovery. Pharm Sci Tech Today 2000; 3: 310-316.
57. He L, Musick MD, Nicewarner SR, Salinas FG, Benkovic SJ, Natan MJ, et al. Colloidal Au-enhanced surface plasmon resonance for ultrasensitive detection of DNA hybridization. J Am Chem Soc 2000; 122: 9071-9077.
58. Natan MJ. In: Feldheim DL, Foss CAJ Ed, Metallic Nanoparticles. Synthesis, characterization and applications. New York-Basel, Marcel Dekker 2002; 183-185.
59. Yonezawa T, Sutoh M, Kunitake T. Practical preparation of size-controlled gold nanoparticles in water. Chem Lett 1997; 619-620.
60. San TK, Pal A, Jana NR, Wang ZL, Pa T. Size controlled synthesis of gold nanoparticles using photochemically prepared seed particles. J Nanopart Res 2001; 3: 257-261.
61. Sun Y, Xia Y. Shape-controlled synthesis of gold and silver nanoparticles. Science 2002; 298: 2176-2179.
62. Brust M, Fink J, Bethell D, Schiffrin DJ, Kiely C. Synthesis and reactions of functionalised gold nanoparticles. Chem Comm 1995; 1655-1656.
63. Chen S, Kimura K. Synthesis and characterisation of carboxilate-modified gold nanoparticles powders dispersible in water. Langmuir 1999; 15: 1075-1082.
64. Kanaras AG, Kamounah FS, Schaumburg K, Kiely CJ, Brust M. Thioalkylated tetraethylene glycol: a new ligand for water soluble monolayer protected gold clusters. Chem Comm 2002; 2294-2295.
65. Aslan K, Pérez-Luna V. Surface modification of colloidal gold bv chemisorption of alkanethiols in presence of a nonionic surfactant. Langmuir 2002; 18: 6059-6065.
66. Elghanian R, Storhoff JJ, Mucic JC, Lestinger RL, Mirkin CA. Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. Science 1997; 277: 1078-1081.
67. Storhoff JJ, Elghanian R, Nucic RC, Mirkin CA, Lestinger RL. One-Pot colorimetric differentiation of polynucleotides with single base imperfections using gold nanoparticles probes. J Am Chem Soc 1998; 120: 1959-1964.
68. Cao YW, Jin R, Mirkin CA. DNA-modified core-shell Ag/Au nanoparticles. J Am Chem Soc 2001; 123: 7961-7962.
69. Otsuka H, Akiyama Y, Nagasaki Y, Kataoka K. Quantitative and reversible lectin-induced association of gold nanoparticles modified with a-lactosyl-w-mercapto-poly(ethyleneglycol). J Am Chem Soc 2001; 123: 8226-8230.
70. Eck D, Helm CA, Wagner NJ, Vaynberg KA. Plasmon resonance measurements of the adsorption and adsorption kinetics of a biopolymer onto gold nanocolloids. Langmuir 2001; 17: 957-960.
71. Englebienne P, Van Hoonacker A, Valsamis J. Rapid homogeneous immunoassay for human ferritin in the Cobas Mira using collooidal gold as reporter reagent. Clin Chem 2000; 46: 2000-2003.
72. Nath N, Chilkoti A. A colorimetric gold nanoparticles sensor to interrogate bomolecular interactions in real time on a surface. Anal Chem 2002; 74: 504-509.
73. Englebienne P. Use of colloidal gold surface plasmon resonance peak shift to infer affinity constants from the interactions between protein antigens and antibodies specific for single or multiple epitopes. Analyst 1998; 123: 1599-1603.
74. Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 2002; 298: 1759-1762.
75. Maxwell DJ, Nie S. Self-assembled nanoparticles probes for recognition and detection of biomolecules. J Am Chem Soc 2002; 124: 9606-9612.
76. Sokolov K, Follen M, Aaron J, Pavlova I, Malpica A, Lotan R, et al. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold particles. Cancer Res 2003; 63: 1999-2004.
77. Talon TA, Lu G, Mirkin CA. Two-color labeling of oligonucleotide arrays via size-selective scattering of nanopaticles probes. J Am Chem Soc 2001; 123: 5164-5165.
78. Schultz S, Smith DR, Mock JJ, Schultz DA. Single-target molecule detection with nonbleaching multicolor optical immunolabels. Proc Nat Acad Sci USA 2000; 97: 996-1001.
79. Service RF. Semiconductor beacons light up cell structures. Science 1998; 281: 1930-1931.
80. Chan WCW, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 1998; 281: 2016-2018.
81. Henglein A. Small-particle research: physicochemical properties of extremely small colloidal metal and semiconductor particles. Chem Rev 1989; 89: 1861-1873.
82. Alivisatos AP. Semiconductor clusters, nanocrystals and quantum dots. Science 1996; 271: 933-937.
83. Murray CB, Norris DJ, Bawendi MG. Synthesis and characterisation of nearly monodisperse CdE (E = S, Se, Te) semiconductor nanocrystallites. J Am Chem Soc 1993; 115: 8706-8715.
84. Peng X, Schlamp MC, Kadavanich AV, Alivisatos AP. Epitaxial growth of highly luminescent CdSe/CdS core/shell nanocrystals with photostability and electronic accessibility. J Am Chem Soc 1997; 119: 7019-7029.
85. Hines MA, Guyot-Sionnest P. Synthesis and characterization of strongly luminescing ZnS-capped CdSe nanocrystals. J Phys Chem 1996; 100: 468-471.
86. Bruchez M, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science 1998; 281: 2013-2016.
87. Hanaki K, Momo A, Oku T, Komoto A, Maenosono S, Yamaguchi Y, et al. Semiconductor quantum dot/albumin complex is a long-life and highly photostable endosome marker. Biochem Biophys Res Comm 2003; 302: 496-501.
88. Jaiswal JK, Mattoussi H, Mauro JM, Simon SM. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol 2003; 21: 47-51.
89. Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2003; 21: 41-46.
90. Dahan M, Lévi S, Luccardini C, Rostaing P, Riveau B, Triller A. Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science 2003; 302: 442-445.
91. Larson DR, Zipfel WR, Williams RM, Clark SW, Bruchez MP, Wise FW, et al. Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science 2003; 300: 1434-1436.
92. Akerman ME, Chan WCW, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 2002; 99: 12617-12621.
93. Mitchell GP, Mirkin CA, Letsinger RL. Programmed assembly of DNA functionalized quantum dots. J Am Chem Soc 1999; 121: 8122-8123.
94. Gerion D, Parak WJ, Williams SC, Zanchet D, Micheel CM, Alivisatios AP. Sorting Fluorescent Nanocrystals with DNA. J Am Chem Soc 2002; 124: 7070-7074.
95. Aldana J, Wang YA, Peng X. Photochemical instability of Cd Se nanocrystals coated by hydrophilic thiols. J Am Chem Soc 2001; 123: 8844-8850.
96. Ness JM, Akhtar RS, Latham CB, Roth KA. Combined tyramide signal amplification and quantum dots for sensitive and photostable immunofluorescence detection. J Histochem Cytochem 2003; 51: 981-987.
97. Klerreich E. Biologists join the dots. Nature 2001; 413: 450-452.
98. Chan WCW, Maxwell DJ, Gao X, Bailey RE, Han M, Nie S. Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol 2002; 13: 40-46.
99. Kemshead JT, Heath L, Gibson FM, Katz F, Richmond F, Treleaven J, et al. Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: experiences, improvements and observations. Br J Cancer 1986; 54: 771-778.
100. De Rosa L, Montuoro A, Lanti T, Pescador L, Morara R, De Laurenzi A. Immunomagnetic purging procedure for autologous bone marrow transplantation in lymphoid malignancies. Haematologica 1991; 76 S1: 37-40.
101. Haukanes B, Kvam C. Application of magnetic beads in bioassays. Biotechnology 1993; 11: 60-63.
102. Miltenyi S, Müller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry 1990; 11: 231-238.
103. Clarke C, Titley J, Davies S, O'Hare MJ. An immunomagnetic separation method using superparamagnetic (MACS) beads for large-scale purification of human mammary luminal and myoepithelial cells. Epith Cell Biol 1994; 3: 38-46.
104. Sieben S, Bergemann C, Lübbe A, Brokmann B, D. Rescheleit D. Comparison of different particles and methods for magnetic isolation of circulating tumor cells. J Magn Magn Mater 2001; 225: 175-179.
105. Partington KM, Jenkinson EJ, Anderson G. A novel method of cell separation based on dual parameter immunomagnetic cell selection. J Immunol Methods 1999, 223: 195-205.
106. Lopez JA, Bioley G, Turtle CJ, Pinzon-Cherry A, Ho CS, Vuckovic S, et al. Single step enrichment of blood dendritic cells by positive selection. J Immunol Methods 2003; 274: 47-61.
107. Bischoff FZ, Marquéz-Do DA, Martinez DI, Dang D, Horne C, Lewis D, et al. Intact fetal cell isolation from maternal blood: improved isolation using a simple whole blood progenitor cell enrichment approach (RosetteSep™). Clin Genet 2003; 63: 483-489.
108. Toba K, Hanawa H, Fuse I, Sakaue M, Watanabe K, Uesugi Y, et al. Difference in CD22 molecules in human B cells and basophils. Exp Hematol 2002; 30: 205-211.
109. Day CL, Seth NP, Lucas M, Appel H, Gauthier L, Lauer GM, et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 2003; 112: 831-842.
110. Begg A, Sprong D, Balm A, Coco Martin JM. Premature chromosome condensation and cell separation studies in biopsies from head and neck tumors for radiosensitivity prediction. Radiother Oncol 2002; 62: 335-343.
111. Kielhorn E, Schofield K, Rimm DC. Use of magnetic enrichment for detection of carcinoma cells in fluid specimens. Cancer 2002; 94: 205-211.
112. Senyei A, Widder K, Czerlinski G. Magnetic guidance of drug-carrying microspheres. J App Phys 1978; 49: 3578-3583.
113. Widder KJ, Morris RM, Poore G, Howard DP, Senyei AE. Tumor remission in Yoshida sarcoma-bearing rats by selective targeting of magnetic albumin microspheres containing doxorubicin. Proc Natl Acad Sci USA 1981; 78: 579-581.
114. Ibrahim A, Couvreur P, Roland M, Speiser P. New magnetic drug carrier. J Pharm Pharmacol 1983; 35: 59-61.
115. Papisov MI, Savelyev VY, Sergienko VB, Torchilin VP. Magnetic drug targeting I. In vivo kinetics of radiolabelled magnetic drug carriers. Int J Pharm 1987; 40: 201-206.
116. Papisov MI, Torchilin VP. Magnetic drug targeting II. Targeted drug transport by magnetic microparticles: factors influencing therapeutic effect. Int J Pharm 1987; 40: 207-214.
117. Lübbe AS, Bergemann C. Magnetically-controlled drug targeting. Cancer J 1998; 11: 104-105.
118. Lübbe A, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. J Surg Res 2001; 95: 200-206.
119. Bergemann C, Müller-Schulte D, Oster J, Brassard L, Lübbe AS. Magnetic ion-exchange nano- and microparticles for medical, biochemical and molecular biological applications. J Magn Magn Mater 1999; 194: 45-52.
120. Lübbe AS, Bergemann C, Brok J, McClure DG. Physiological aspects in magnetic drug-targeting. J Magn Magn Mater 1999; 194: 149-155.
121. Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 1996; 56: 4694-4701.
122. Lübbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, et al. Clinical experiences with magnetic drug targeting: a phase I study with 4′ - epidoxorubicin in 14 patiens with advanced solid tumors. Cancer Res 1996; 56: 4686-4693.
123. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, et al. Locoregional cancer treatement with magnetic targeting. Cancer Res 2000; 60: 6641-6648.
124. Alexiou C, Jurgons R, Schmidt RJ, Bergemann C, Henke J, Erhardt W, et al. Magnetic drug targeting - Biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target 2003; 11: 139-149.
125. Rudge SR, Kurtz TL, Vessely CR, Catterall LG, Williamson DL. Preparation, characterization and performance of magnetic iron-carbon composite microparticles for chemotherapy. Biomater 2000; 21: 1411-1420.
126. Rudge S, Peterson C, Vessely C, Koda J, Stevens S, Catterall L. Adsorption and desorption of chemotherapeutic drugs from a magnetically targeted carrier (MTC). J Control Release 2001; 74: 335-340.
127. Goodwin S, Peterson C, Hoh C, Bittner C. Targeting and retention of magnetic targeted carriers (MTCs) enhancing intra-arterial chemotherapy. J Magn Magn Mater 1999; 194: 132-139.
128. Leakakos T, Ji C, Lawson G, Peterson C, Goodwin S. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol 2003; 51: 445-450.
129. Arias JL, Gallardo V, Gomez-Lopera SA, Plaza RC, Delgado AV. Synthesis and characterisation of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Control Release 2001; 77: 309-321.
130. Chen H, Langer R. Magnetically-responsive polymerized liposomes as potential oral delivery vehicles. Pharm Res 1997; 14: 537-540.
131. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int J Oncol 2001; 18: 121-125.
132. Jain S, Mishra V, Singh P, Dubey PK, Saraf DK, Vyas SP. RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int J Pharm 2003; 261: 43-55.
133. Hsieh D, Langer R Folkman J. Magnetic modulation of release of macromolecules forn polymers. Proc Natl Acad Sci USA 1981; 78: 1863-1867.
134. Edelman ER, Kost J, Bobeck T, Langer R. Regulation of drug release from polymer matrices by oscillating magnetic fields. J Biomed Mat Res 1985; 19: 67-83.
135. Kost J, Noecker R, Kunica E Langer R. Magnetically controlled release systems: effect of polymer composition. J Biomed Mat Res 1985; 19: 935-940.
136. Kost J, Wolfrum J, Langer R. Magnetically enhanced insulin release in diabetic rats. J Biomed Mat Res 1987; 21: 1367-1373.
137. Saslawski O, Weingarten C, Benoît JP, Couvreur P. Magnetically responsive microspheres for the pulsed delivery of insulin. Life Sci 1988; 42: 1521-1528.
138. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001; 53: 285-305.
139. Chilkoti A, Dreher M, Meyer DE Raucher D. Targeted drug delivery by thermally responsive polymers. Adv Drug Deliv Rev 54: 613-630.
140. West JL, Halas NJ. Applications of nanotechnology to biotechnology. Curr Opin Biotechnol 2000; 11: 215-217.
141. Averitt RD, Westcott SL, HalasNJ. Linear optical properties of gold nanoshells. J Opt Soc Am B 1999; 16: 1824-1832.
142. 2S nanoshells: insight into multicomponent nanoparticle growth. Phys Rev Lett 1997; 78: 4217-4220.
143. Sershen SR, Westcott SL, Halas NJ, West JL. Temperature-sensitive polymer-nanoshell composites for photothermally modulated drug delivery. J Biomed Mat Res 2000; 51: 293-298.
144. Sershen SR, Westcott SL, West JL, Halas NJ. An opto-mechanical nanoshell-polymer compsite. Appl Phys B 2001; 73: 379-381.
145. Klein TM, Fitzpatrick-McElligott S. Particle bombardement: a universal approach for gene transfer to cells and tissues. Curr Opin Biotechnol 1993; 4: 583-590.
146. Haynes JR, McCabe DE, Swain WF, Widera G, Fuller JT. Particle-mediated nucleic acid immunization. J Biotechnol 1996; 44: 37-42.
147. Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH, Haynes JR. Gene Gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 1995; 15: 1427-1430.
148. Tachedjian M, Boyle JS, Lew AM, Hrovatic B, Scheerlink JPY, Tennent JM, et al. Gene Gun immunization in a preclinical model is enhanced by B7 targeting. Vaccine 2003; 21: 2900-2905.
149. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal and Gene-Gun inoculations. Proc Natl Acad Sci USA 1993; 90: 11478-11482.
150. Wang J, Murakami T, Yoshida S, Matsuoka H, Ishii A, Tanaka T, et al. Predominant cell-mediated immunity in the oral mucosa: Gene Gun-based vaccination against infectious diseases. J Dermatol Sci 2003; 31: 203-210.
151. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered trough Gene Gun, Biojector, and syringe. Vaccine 2003; 21: 4036-4042.
152. Sun WH, Burkholder JK, Sun J, Culp J, Turner J, Lu XG, et al. In vivo cytokine gene transfer by Gene Gun reduces tumor growth in mice. Proc Natl Acad Sci USA 1995; 92: 2889-2893.
153. Seigne J, Turner J, Diaz J, Hackney J, Pow-Sang J, Helal H, et al. A feasibility study of Gene Gun mediated immunotherapy for renal cell carcinoma. J Urol 1999; 162: 1259-1263.
154. Plank C, Anton M, Rudolph C, Rosenecker J, Krötz F. Enhancing and targeting nucleic acid delivery by magnetic force. Exp Opin Biol Ther 2003; 3: 745-758.
155. Plank C, Scherer F, Schillinger U, Bergemann C, Anton M. Magnetofection: enhancing and targeting gene delivery with superparamagnetic nanoparticles and magnetic fields. J Liposome Res 2003; 13: 29-32.
156. Plank C, Schillinger U, Scherer F, Bergemann C, Rémy JS, Krötz F, et al. The magnetofection method: using magnetic force to enhance gene delivery. Biol Chem 2003; 384: 737-747.
157. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Krüger A, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002; 9: 102-109.
158. Krötz F, de Wit C, Sohon HY, Zahler S, Gloe T, Pohl U, et al. Magnetofection - A highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther 2003; 7: 700-710.
159. Hirao K, Sugita T, Kubo T, Igarashi K, Tanimoto K, Murakami T, et al. Targeted gene delivery to human osteosarcoma cells with magnetic cationic liposomes under a magnetic field. Int J Oncol 2003; 22: 1065-1071.
160. Engin K. Biological rationale and clinical experience with hyperthermia. Control Clin Trials 1996; 17: 316-342.
161. Takahashi I, Emi Y, Hasuda S, Kakeji Y, Maehara Y, Sugimachi K. Clinical application of hyperthermia combined with anticancer drugs for the treatment of solid tumors. Surgery 2002; 131: S78-S84.
162. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002; 43: 33-56.
163. van der Zee J. Heating the patient: a promising approach? Ann Oncol 2002; 13: 1173-1184.
164. Moroz P, Jones SK, Gray BN. Magnetically mediated hyperthermia: current status ans future directions. Int J Hyperthermia 2002; 18: 267-284.
165. Jordan A, Wust P, Fähling H, Krause J, Felix R. In: Hatch U, Shutt W, Teller J, Zobrowski M Ed, Scientific and Clinical Applications of Magnetic Carriers, New York, Plenum Press 1997; 569-575.
166. Jordan A, Wust P, Fähling H, John W, Hinz A, Felix R. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia 1993; 9: 51-68.
167. Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parott JC, Taylor CB. Selective inductive heating of lymph nodes. Ann Surg 1957; 146: 596-606.
168. Gordon RT, Hines JR, Gordon D. Intracellular hyperthermia. A biophysical approach to cancer treatment via intracellular temperature and biophysical alteration. Med Hypotheses 1979; 5: 83-102.
169. Brusentov N, Gogosov VV, Brusentova TN, Sergeev AV, Jurchenko NY, Kuznetsov AA, et al. Evaluation of ferromagnetic fluids and suspensions for the site-specific radiofrequency-induced hyperthermia of MX11 sarcoma cells in vitro. J Magn Magn Mater 2001; 225: 113-117.
170. Rand RW, Snyder M, Elliot D, Snow H. Selective radiofrequency heating of ferrosilicone occluded tissue. Bull Los Angeles Neurol Soc 1976; 41: 154-159.
171. Jones SK, Winter JG, Gray BN. Treatement of experimental rabbit liver tumors by selectively targeted hyperthermia. Int J Hyperthermia 2002; 18: 117-128.
172. Moroz P, Jones SK, Gray BN. Arterial embolization hyperthermia in porcine renal tissue. J Surg Res 2002, 105: 209-214.
173. Moroz P, Jones SK, Gray BN. The effect of tumor size on ferromagnetic embolization hyperthermia in a rabbit liver tumor model. Int J Hyperthermia 2002, 18: 129-140.
174. Sato T, Masai A, Ota Y, Sato H, Matuski H, Yanada T, et al. The development of anticancer agent releasing microcapsule made of ferromagnetic amorphous flakes for intratissue hyperthermia. IEEE Trans Magn 1993; 29: 3325-3330.
175. Shinkai M, Yanase M, Suzuki M, Honda H, Wakabayashi T, Yoshida J, et al. Intracellular hyperthermia for cancer using magnetite cationic liposomes. J Magn Magn Mater 1999; 194: 176-184.
176. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes. Jpn J Cancer Res 1998; 89: 775-782.
177. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study. Jpn J Cancer Res 1998; 89: 463-469.
178. Hilger I, Andrä W, Hergt R, Hiergeist R, Schubert H, Kaiser WA. Electromagnetic heating of breast tumors in interventional radiology: in vitro and in vivo studies in human cadavers and mice. Radiology 2001; 218: 570-575.
179. Hilger I, Hiergeist R, Hergt R, Winnefeld K, Schubert H, Kaiser WA. Thermal ablation of tumors using magnetic nanoparticles. An in vivo feasibility study. Invest Radiol 2002; 37: 580-586.
180. Jordan A, Scholz R, Maier-Hauff K, Johannsen M, Wust P, Nadobny J, et al. Presentation of a new magnetic field therapy system for the treatement of human solid tumors with magnetic fluid hyperthermia. J Magn Magn Mater 2001; 225: 118-126.
181. Halbreich A, Roger J, Pons JN, Geldwerth D, Da Silva MF, Roudier M, et al. Biomedical applications of maghemite ferrofluids. Biochimie 1998; 80: 379-390.
182. Bacri JC, Da Silva MF, Perzynski R, Pons JN, Roger J, Sabolovic D, et al. In: Hafeli U, Shutt W, Teller J, Zobrowski M Ed, Scientific and Clinical Applications of Magnetic Carriers, New York, Plenum Press 1997; 597-606.
183. Jordan A, Scholz R, Wust P, Schirra H, Schiestel T, Schmidt H, et. al. Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro. J Magn Magn Mater 1999; 194: 185-196.
184. Shinkai M, Le B, Honda H, Yoshikawa K, Shimizu K, Saga S, et al. Targeting hyperhtermia for renal cell carcinoma using human MN antigen-specific magnetoliposomes. Jpn J Cancer Res 2001; 92: 1138-1145.
185. Pitsillides CM, Joe EK, Wei X, Anderson RR, Lin CP, Selective cell targeting with light-adsorbing microparticles and nanoparticles. Biophys J 2003; 84: 4023-4032.
186. Lin CP, Kelly MW, Sibayan SAB, Latina MA, Anderson RR. Selective cell killing by microparticle absorption of pulsed laser radiation. IEEE J Quantum Elect 1999; 5: 963-968.